BTIG initiated coverage of I-Mab (IMAB) with a Buy rating and $7 price target The firm believes givastomig has “best-in-class potential” to redefine first-line gastric cancer treatment. Unlike Zolbetuximab, givastomig’s 10-times more potent conditional 4-1BB design drives activity across CLDN18.2-low and PD-L1-low populations, which doubles the addressable market, the analyst tells investors in a research note. BTIG believes the drug’s early durability and “clean” safety profile validate its “differentiated mechanism.” It sees a near-term catalyst for I-Mab shares with a Q1 of 2026 data release.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMAB:
- I-Mab’s Strategic Expansion and Financial Stability Justify Buy Rating Amid Promising Clinical Developments
- I-Mab announces accelerated investment in givastomig program
- I-Mab Announces Leadership Changes and Accelerated Investment in Givastomig
- I-Mab Strengthens Leadership with New Board Appointments and R&D Committee Formation
- I-Mab appoints Lenz, Liu to board of directors, forms R&D Committee